STAT+: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices
NEW YORK — Biotech investors don’t often publicly lay out their strategies, but an executive with a top investment firm on Tuesday offered a rare glimpse into the math he and others like him are doing after Democrats empowered Medicare to negotiate drug prices.
Peter Thompson, a general partner at investment giant OrbiMed Advisors who has spent around four decades in oncology drug development, laid out several ways the law will steer capital to a packed audience at a New York City conference sponsored by the Biotechnology Innovation Organization.
Continue to STAT+ to read the full story…
Biotech investors don’t often lay out their strategies, but one offered a rare glimpse into what he’s doing after Democrats empowered Medicare to negotiate drug prices.
Information Courtesy By: Rachel Cohrs, #HealthcareNews #Healthcare | Feeds
NEW YORK — Biotech investors don’t often publicly lay out their strategies, but an executive with a top investment firm on Tuesday offered a rare glimpse into the math he and others like him are doing after Democrats empowered Medicare to negotiate drug prices.
Peter Thompson, a general partner at investment giant OrbiMed Advisors who has spent around four decades in oncology drug development, laid out several ways the law will steer capital to a packed audience at a New York City conference sponsored by the Biotechnology Innovation Organization.
Continue to STAT+ to read the full story…
Biotech investors don’t often lay out their strategies, but one offered a rare glimpse into what he’s doing after Democrats empowered Medicare to negotiate drug prices.
Click For More Details
2023-02-08 02:23
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.